Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance

被引:72
作者
Crane, Christopher H. [1 ]
Koay, Eugene J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 97, Houston, TX 77030 USA
关键词
gating; hepatoma; image-guided radiation therapy (IGRT); intrahepatic cholangiocarcinoma; stereotactic ablative radiation therapy; BODY RADIATION-THERAPY; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; PROTON-BEAM THERAPY; HEPATOCELLULAR-CARCINOMA; 2-STAGE HEPATECTOMY; PHASE-II; DISEASE; CANCER; TRIAL; LUNG;
D O I
10.1002/cncr.29878
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The emergence and success of stereotactic body radiation therapy (SBRT) for the treatment of lung cancer have led to its rapid adoption for liver cancers. SBRT can achieve excellent results for small liver tumors. However, the vast majority of physicians interpret SBRT as meaning doses of radiation (range, 4-20 Gray [Gy]) that may not be ablative but are delivered within about 1 week (ie, in 3-6 fractions). Adherence to this approach has limited the effectiveness of SBRT for large liver tumors (>7cm) because of the need to reduce doses to meet organ constraints. The prognosis for patients who present with large liver tumors is poor, with a median survival 12 months, and most of these patients die from tumor-related liver failure. Herein, the authors present a comprehensive solution to achieve ablative SBRT doses for patients with large liver tumors by using a combination of classic, modern, and novel concepts of radiotherapy: fractionation, dose painting, motion management, image guidance, and simultaneous integrated protection. The authors discuss these concepts in the context of large, inoperable liver tumors and review how this approach can substantially prolong survival for patients, most of whom otherwise have a very poor prognosis and few effective treatment options. Cancer 2016;122:1974-86. (c) 2016 American Cancer Society. Ablation of large liver tumors can be routinely achieved with radiation if high enough doses are used (biologic equivalent dose of 100 Gray). For tumors near bowel, this requires a solution for organ motion, high-quality soft tissue image guidance, and a stereotactic body radiation therapy technique with 15 to 25 rather than 5 fractions.
引用
收藏
页码:1974 / 1986
页数:13
相关论文
共 62 条
[1]   Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors [J].
Adam, R ;
Laurent, A ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2000, 232 (06) :777-784
[2]   Stereotactic radiation therapy for liver metastases: factors affecting local control and survival [J].
Andratschke, Nicolaus H. J. ;
Nieder, Carsten ;
Heppt, Franz ;
Molls, Michael ;
Zimmermann, Frank .
RADIATION ONCOLOGY, 2015, 10
[3]   DOSE VOLUME HISTOGRAM ANALYSIS OF LIVER RADIATION TOLERANCE [J].
AUSTINSEYMOUR, MM ;
CHEN, GTY ;
CASTRO, JR ;
SAUNDERS, WM ;
PITLUCK, S ;
WOODRUFF, KH ;
KESSLER, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1986, 12 (01) :31-35
[4]   Differential hepatic avoidance radiation therapy: Proof of concept in hepatocellular carcinoma patients [J].
Bowen, Stephen R. ;
Saini, Jatinder ;
Chapman, Tobias R. ;
Miyaoka, Robert S. ;
Kinahan, Paul E. ;
Sandison, George A. ;
Wong, Tony ;
Vesselle, Hubert J. ;
Nyflot, Matthew J. ;
Apisarnthanarax, Smith .
RADIOTHERAPY AND ONCOLOGY, 2015, 115 (02) :203-210
[5]   Respiratory gating with EPID-based verification: the MDACC experience [J].
Briere, Tina Marie ;
Beddar, Sam ;
Balter, Peter ;
Murthy, Ravi ;
Gupta, Sanjay ;
Nelson, Christopher ;
Starkschall, George ;
Gillin, Michael T. ;
Krishnan, Sunil .
PHYSICS IN MEDICINE AND BIOLOGY, 2009, 54 (11) :3379-3391
[6]   Adaptive Management of Liver Cancer Radiotherapy [J].
Brock, Kristy K. ;
Dawson, Laura A. .
SEMINARS IN RADIATION ONCOLOGY, 2010, 20 (02) :107-115
[7]   Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma [J].
Bujold, Alexis ;
Massey, Christine A. ;
Kim, John J. ;
Brierley, James ;
Cho, Charles ;
Wong, Rebecca K. S. ;
Dinniwell, Rob E. ;
Kassam, Zahra ;
Ringash, Jolie ;
Cummings, Bernard ;
Sykes, Jenna ;
Sherman, Morris ;
Knox, Jennifer J. ;
Dawson, Laura A. .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (13) :1631-+
[8]   Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials [J].
Chang, Joe Y. ;
Senan, Suresh ;
Paul, Marinus A. ;
Mehran, Reza J. ;
Louie, Alexander V. ;
Balter, Peter ;
Groen, Harry J. M. ;
McRae, Stephen E. ;
Widder, Joachim ;
Feng, Lei ;
van den Borne, Ben E. E. M. ;
Munsell, Mark F. ;
Hurkmans, Coen ;
Berry, Donald A. ;
van Werkhoven, Erik ;
Kresl, John J. ;
Dingemans, Anne-Marie ;
Dawood, Omar ;
Haasbeek, Cornelis J. A. ;
Carpenter, Larry S. ;
De Jaeger, Katrien ;
Komaki, Ritsuko ;
Slotman, Ben J. ;
Smit, Egbert F. ;
Roth, Jack A. .
LANCET ONCOLOGY, 2015, 16 (06) :630-637
[9]   THE EFFECT OF EXTERNAL RADIOTHERAPY IN TREATMENT OF PORTAL-VEIN INVASION IN HEPATOCELLULAR-CARCINOMA [J].
CHEN, SC ;
LIAN, SL ;
CHANG, WY .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 33 :S124-S127
[10]   Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease [J].
Cheng, JCH ;
Wu, JK ;
Lee, PCT ;
Liu, HS ;
Jian, JJM ;
Lin, YM ;
Sung, JL ;
Jan, GJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (05) :1502-1509